Indication

Lialda is indicated for the induction of remission in patients with active, mild to moderate ulcerative colitis (UC) and for the maintenance of remission of UC.

Important Safety Information

  • Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda.
  • Renal impairment, including minimal change nephropathy, acute and chronic interstitial nephritis, and, rarely, renal failure, has been reported with products such as Lialda that contain mesalamine or are converted to mesalamine. It is recommended that patients have an evaluation of renal function prior to initiating use of Lialda and periodically while on therapy. Exercise caution when using Lialda in patients with known renal dysfunction or a history of renal disease.

Read More Below

This site is intended for US health care professionals. Patient Site
For active, mild to moderate ulcerative colitis (UC)

Important Safety Information

Lialda is contraindicated in patients with known hypersensitivity to salicylates or aminosalicylates or to any of the ingredients of Lialda. See Important Safety Information

Lialda® (mesalamine): #1 Prescribed 5-ASA Among Gastroenterologists1

Lialda Formulary Coverage

Select a state below to see the top 5 results*, or manually select from all the plans within that state.

We can offer you localized results. Select your choice when prompted.

Step 1:
Step 2:

Select Plan Type

Close

[Plan Name]

Plan Name Status Copay/
Co-Ins
Product Status Copay/
Co-Ins
Plan Name Lialda  Asacol® HD Apriso® Delzicol®

Select Plan in [State]

Select Plan Type


Beginning with:

0 Plans selected
Close

Formulary Coverage Key4,5

  • Tier 1: These drugs are available at the lowest copay. Most commonly, these are generic drugs.
  • Tier 2: These drugs are available at a middle-level copay. Most commonly, these are "preferred" (on formulary) brand drugs.
  • Tier 3P: These drugs are available at a preferred copay. Most commonly used when Tiers 1 and 2 apply to preferred generic and non-preferred generic drugs, respectively.
  • Tier 3: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs.
  • Tier 4: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
  • Tier >4: These drugs are available at a higher-level copay. Most commonly, these are "non-preferred" brand drugs or specialty prescription products.
  • N/A: Not Available. Formulary data for this drug/health plan are not available.
  • NC: Not Covered. Drugs that are not covered by the plan.
  • PA: Prior Authorization. This restriction requires that specific clinical criteria be met prior to the approval of the prescription.
  • QL: Quantity Limits. Drugs that have quantity limits associated with each prescription. This restriction typically limits the quantity of drug that will be covered.
  • ST: Step Therapy. This restriction typically requires that certain criteria be met prior to approval for the prescription.

E-mail Results

Close

Name

*Required field

*E-mail Address

All personal information you have provided will be kept confidential and will not be shared, except in accordance with our Privacy Policy Statement. We encourage you to read our Privacy Policy Statement by clicking on this link: Review Shire Privacy Policy Statement.

Send

Thank you, your e-mail has been sent.

Back to top Back to top

Back to top Back to top